Viridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $30.00 by Analysts at Royal Bank Of Canada

Viridian Therapeutics (NASDAQ:VRDN) had its price objective reduced by Royal Bank Of Canada from $42.00 to $30.00 in a research note released on Tuesday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

VRDN has been the topic of a number of other research reports. Needham & Company LLC cut their price objective on shares of Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Wall Street Zen downgraded shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Evercore reaffirmed an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Finally, Truist Financial cut their price objective on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Viridian Therapeutics Trading Up 0.4%

Shares of NASDAQ:VRDN opened at $13.96 on Tuesday. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $34.29. The business’s fifty day simple moving average is $27.58 and its 200-day simple moving average is $27.82. The company has a market capitalization of $1.43 billion, a PE ratio of -4.24 and a beta of 1.16. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $15.75 million. As a group, equities research analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd purchased a new stake in Viridian Therapeutics during the 3rd quarter worth approximately $35,000. ANTIPODES PARTNERS Ltd purchased a new stake in Viridian Therapeutics during the 4th quarter worth approximately $36,000. Farther Finance Advisors LLC grew its position in Viridian Therapeutics by 332.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after purchasing an additional 1,491 shares during the last quarter. Bessemer Group Inc. grew its position in Viridian Therapeutics by 947.7% during the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after purchasing an additional 1,886 shares during the last quarter. Finally, Larson Financial Group LLC purchased a new stake in Viridian Therapeutics during the 3rd quarter worth approximately $52,000.

Key Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Goldman Sachs cut its price target from $36 to $31 but kept a “buy” rating, implying substantial upside versus the current price and signaling continued analyst conviction. Benzinga
• Positive Sentiment: Royal Bank of Canada lowered its target from $42 to $30 but retained an “outperform” rating, again indicating analysts still see long‑term value despite near‑term headwinds. Benzinga
• Neutral Sentiment: Coverage roundup: a Globe & Mail piece groups Viridian with other healthcare names and summarizes recent analyst commentary — useful context but no new company‑specific catalyst. Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)
• Negative Sentiment: Competitive clinical risk: Amgen reported positive Phase 3 results for a thyroid eye disease program (TEPEZZA OBI trial reported a 77% proptosis response), which investors view as direct competition to Viridian’s lead program and has been cited as a main reason for recent selling pressure. Why Is Viridian Therapeutics Stock Sinking Monday?
• Negative Sentiment: Press coverage highlights the Amgen link as the driver of the drop, increasing investor concern about VRDN’s addressable market and near‑term commercial prospects. Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.
• Negative Sentiment: Sentiment/flow signal: unusual options activity — ~7,501 put contracts purchased (a large multiple of typical volume) — indicating hedging or speculative bearish bets that can accelerate downside moves in volatile sessions.
• Negative Sentiment: MSN and other outlets note VRDN has fallen to 9‑month lows amid the Amgen developments, underscoring the short‑term negative narrative investors are reacting to. VRDN stock falls to 9-month lows – what’s the Amgen connection?

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.